Trial · NCT00739934
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration | Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method. |
| Primary | Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration | Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | |
| Primary | Time to Reach Cmax (Tmax) Following IV Administration | Day 7 (up to Day 20 or more) at predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | |
| Primary | AUC12,ss Following Oral Administration | Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose | AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method. |
| Primary | Cmax,ss Following Oral Administration | Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose | |
| Primary | Tmax Following Oral Administration | Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose | |
| Secondary | AUC12 Following IV Loading Dose | Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method. |
| Secondary | Cmax Following an IV Loading Dose | Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | |
| Secondary | Tmax Following an IV Loading Dose | Day 1 predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | |
| Secondary | Trough Concentrations (Cmin) | Day 7 (up to Day 20 or more) for IV; Day 7 (or later) for oral at predose | |
| Secondary | AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration | Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method. |
| Secondary | Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration | Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | |
| Secondary | Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration | Days 1 and 7 (up to Day 20 or more) predose, 60 and 138 minutes, 4, 6, 8 and 12 hours postdose | Zero Tmax refers to the highest concentration observed for one participant at predose. The profile of the metabolite is relatively flat, which could result in slight variation in sample collection or assay process. |
| Secondary | AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose | AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method. |
| Secondary | Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose | |
| Secondary | Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | Day 7 (or later) predose, 1, 2, 4, 6, 8 and 12 hours postdose |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00739934/registered